Substance / Medication

Enfortumab vedotin

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
2
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma: A systematic review and meta-analysis.
Gazzoni Gabriela, Michelon Isabella, Vilbert Maysa et al. · Urol Oncol · 2025
PMID: 40592676Meta-Analysis
Increased Risk of Hyperglycemia in Advanced Urothelial Cancer Patients Treated with Enfortumab Vedotin: A Systematic Review and Meta-Analysis.
Cheng Ryan, Boparai Montek, Zhu Xiaolei et al. · Cancer Invest · 2025
PMID: 40358559Meta-Analysis
Enfortumab Vedotin With or Without Pembrolizumab in Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Yajima Shugo, Hirose Kohei, Masuda Hitoshi · JAMA Netw Open · 2025
PMID: 40067303Meta-AnalysisFull text (PMC)
Survival outcomes with enfortumab vedotin-containing regimens in metastatic urothelial carcinoma: A systematic review and meta-analysis.
Ansab Muhammad, Rath Shree, Ishaque Ghazal et al. · Crit Rev Oncol Hematol · 2025
PMID: 40972693Meta-Analysis
Efficacy and safety of enfortumab vedotin in the treatment of advanced urothelial carcinoma: a systematic review and meta-analysis.
Wang Leibo, Shi Guanyu, Zhao Guoqiang et al. · Anticancer Drugs · 2023
PMID: 36730481Meta-Analysis
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.
Brave Michael H, Maguire William F, Weinstock Chana et al. · Clin Cancer Res · 2024
PMID: 39230571RCTFull text (PMC)
Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.
Lacouture Mario E, Patel Anisha B, Rosenberg Jonathan E et al. · Oncologist · 2022
PMID: 35274723RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Enfortumab vedotin (substance)
SNOMED CT
838468009
UMLS CUI
C4519740

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.